Metahydroxylamine bitartrate injection

This product mainly acts on alpha receptors, directly stimulating alpha receptors. Its effect is weaker than that of norepinephrine but more persistent. Its cardiovascular effect is similar to that of norepinephrine. It can constrict blood vessels, continuously increase systolic and diastolic blood pressure, and enhance myocardial contractility. The cardiac output of normal people does not change much, but it can increase the cardiac output of patients with shock. The excitement of heart rate is not very significant, rarely causes arrhythmia, and has no central nervous system excitation effect. Because its pressor effect is reliable and lasts for a long time, it rarely causes reactions such as palpitations or decreased urine volume. When administered continuously, because this product indirectly replaces the transmitter in the adrenergic nerve vesicles, it can reduce the transmitter and weaken the intrinsic effect. Therefore, it should not be stopped suddenly to avoid rebound hypotension.

The chemical name of this product is: (-)-alpha;(1-aminoethyl)-3-hydroxybenzyl alcohol bitartrate. Molecular formula: C9H13NO2C4H6O6 Molecular weight: 317.29.

This product is a colorless clear liquid.

①Prevention and treatment of acute hypotension during spinal block anesthesia; ②This product can be used as an auxiliary symptomatic treatment for hypotension caused by bleeding, drug allergy, surgical complications, brain trauma or brain tumor combined with shock; ③It can also be used for hypotension caused by cardiogenic shock or sepsis.

1① Intramuscular or subcutaneous injection: 2-10 mg (1/5-1 stick) times (calculated as metaraminol). Since the maximum effect is not immediately apparent, the initial dose effect should be observed for at least 10 minutes before repeated use; ② Intravenous injection, the initial dose is 0.5-5 mg (1/20-1/2 stick), followed by intravenous drip, for severe shock; ③ Intravenous drip, add 15-100 mg (1.5-10 sticks) of metaraminol to 500 ml of 5% glucose solution or sodium chloride injection and drip, and adjust the drip rate to maintain appropriate blood pressure. The maximum dose for adults is 100 mg (10 sticks) at a time (0.3-0.4 mg per minute). 2 Pediatric dosage: ① Intramuscular or subcutaneous injection: 0.1 mg/kg, for severe shock; ② Intravenous drip 0.4 mg/kg or 12 mg/m2 per body surface area, diluted with sodium chloride injection to a solution containing 1 mg of metaraminol per 25 ml, and the drip rate is to maintain an appropriate blood pressure level. The preparation should be used within 24 hours, and other drugs that are poorly soluble in acidic solutions and are incompatible with it should not be added to the infusion solution.

1 Arrhythmia. The incidence rate varies with dosage and patient sensitivity. 2 Too fast and too strong a pressor response can cause acute pulmonary edema, arrhythmia, and cardiac arrest. 3 Overdose is manifested by convulsions, severe hypertension, and severe arrhythmia. At this time, the drug should be stopped immediately for observation. Those with high blood pressure can be given 5-10 mg of phentolamine intravenously, which can be repeated if necessary. 4 When the drug overflows during intravenous administration, it can cause severe contraction of local blood vessels, leading to tissue necrosis and erosion or redness, swelling, and nodules to form abscesses. 5 Hypotension may occur if the drug is suddenly stopped after long-term use.

Not yet clear.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. When used in combination with cyclopropane, halothane or other halogenated hydroxyl anesthetics, it is easy to cause arrhythmia. 2. When used in combination with monoamine oxidase inhibitors, the pressor effect is enhanced, causing severe hypertension. 3. When used in combination with digitalis or other adrenergic drugs, it can cause ectopic rhythm. 4. It is not suitable to be infused together with alkaline drugs, because it can cause the decomposition of this product.

Keep away from light and store in sealed container.

Based on C9H13NO2 1ml:10mg

18 months

Beijing Yongkang Pharmaceutical Co., Ltd.

• Founded in:

  1980-06-18

• Address:

  No. 2, Section 3, Guba Road, Chengguan Street, Fangshan District, Beijing

• Tax NO.:

  91110106802219135P

• Registered Funds:

  20 million yuan

• Website:

  Log in to view

• Email:

  Log in to view